Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Overview
Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Companies Involved in Therapeutics Development
CombiGene AB
Gila Therapeutics Inc
Takeda Pharmaceutical Co Ltd
XL-protein GmbH
Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Drug Profiles
CG-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GT-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GT-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PYY-1119 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XL-310 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Dormant Products
Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Discontinued Products
Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Product Development Milestones
Featured News & Press Releases
Oct 01, 2020: CombiGene one step closer to clinical trials
Sep 28, 2020: CombiGene launches large-scale production of CG01 for upcoming safety and biodistribution studies
Sep 15, 2020: CombiGene and CGT Catapult collaboration completes development of quality control alytical assays for clinical production of CombiGene’s AAV-based gene therapy for the treatment of epilepsy
Sep 11, 2020: CombiGene’s new agreement important for future clinical studies
Sep 03, 2020: CombiGene signs production agreement with Spanish gene therapy manufacturer Viralgen
Aug 18, 2020: Cobra Biologics completes production of Master Cell Banks for CombiGene’s epilepsy gene therapy drug candidate
Aug 10, 2020: CombiGene has completed a successful pilot production of CG01 using Viralgen’s suspension manufacturing platform
Aug 06, 2020: Results from CombiGene’s cell tropism study confirm that CG01 only reaches the nerve cells in the hippocampus
Jul 13, 2020: Cobra Biologics delivers fil plasmids for production of CG01 in CombiGene’s epilepsy project
Mar 24, 2020: CombiGene has concluded a successful learning and memory study in the CG01 epilepsy project.
Mar 20, 2020: CombiGene has concluded the planned pharmacokinetic study in the CG01 epilepsy project with promising results.
Jan 21, 2020: CombiGene receives the second instalment of EUR 1.21 million from Horizon 2020
Dec 19, 2019: Study in human brain tissue shows that NPY can suppress epileptic activity via Y2-receptor activation
Nov 18, 2019: CombiGene receives a second payment of EUR 1.21 million from Horizon 2020
Nov 06, 2019: CombiGene: Two significant steps towards the first human studies for CG01
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Top 10 Indications, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020


List of Tables


Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indication, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by CombiGene AB, H2 2020
Pipeline by Gila Therapeutics Inc, H2 2020
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2020
Pipeline by XL-protein GmbH, H2 2020
Dormant Projects, H2 2020
Discontinued Products, H2 2020